OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Linagliptin Lowers Albuminuria on Top of Recommended Standard Treatment in Patients With Type 2 Diabetes and Renal Dysfunction
Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic, et al.
Diabetes Care (2013) Vol. 36, Iss. 11, pp. 3460-3468
Open Access | Times Cited: 280
Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic, et al.
Diabetes Care (2013) Vol. 36, Iss. 11, pp. 3460-3468
Open Access | Times Cited: 280
Showing 1-25 of 280 citing articles:
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, et al.
JAMA (2018) Vol. 321, Iss. 1, pp. 69-69
Open Access | Times Cited: 965
Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen, et al.
JAMA (2018) Vol. 321, Iss. 1, pp. 69-69
Open Access | Times Cited: 965
Diabetic kidney disease
Merlin C. Thomas, Michael Brownlee, Katalin Suszták, et al.
Nature Reviews Disease Primers (2015) Vol. 1, Iss. 1
Open Access | Times Cited: 918
Merlin C. Thomas, Michael Brownlee, Katalin Suszták, et al.
Nature Reviews Disease Primers (2015) Vol. 1, Iss. 1
Open Access | Times Cited: 918
Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Michael A. Nauck, Juris J. Meier, Matthew A. Cavender, et al.
Circulation (2017) Vol. 136, Iss. 9, pp. 849-870
Open Access | Times Cited: 500
Michael A. Nauck, Juris J. Meier, Matthew A. Cavender, et al.
Circulation (2017) Vol. 136, Iss. 9, pp. 849-870
Open Access | Times Cited: 500
Update of pathophysiology and management of diabetic kidney disease
Yi‐Chih Lin, Yu-Hsing Chang, Shao‐Yu Yang, et al.
Journal of the Formosan Medical Association (2018) Vol. 117, Iss. 8, pp. 662-675
Open Access | Times Cited: 479
Yi‐Chih Lin, Yu-Hsing Chang, Shao‐Yu Yang, et al.
Journal of the Formosan Medical Association (2018) Vol. 117, Iss. 8, pp. 662-675
Open Access | Times Cited: 479
Linagliptin-Mediated DPP-4 Inhibition Ameliorates Kidney Fibrosis in Streptozotocin-Induced Diabetic Mice by Inhibiting Endothelial-to-Mesenchymal Transition in a Therapeutic Regimen
Keizo Kanasaki, Sen Shi, Megumi Kanasaki, et al.
Diabetes (2014) Vol. 63, Iss. 6, pp. 2120-2131
Open Access | Times Cited: 330
Keizo Kanasaki, Sen Shi, Megumi Kanasaki, et al.
Diabetes (2014) Vol. 63, Iss. 6, pp. 2120-2131
Open Access | Times Cited: 330
GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, et al.
Nature Reviews Nephrology (2017) Vol. 13, Iss. 10, pp. 605-628
Closed Access | Times Cited: 314
Marcel H.A. Muskiet, Lennart Tonneijck, Mark M. Smits, et al.
Nature Reviews Nephrology (2017) Vol. 13, Iss. 10, pp. 605-628
Closed Access | Times Cited: 314
Diagnosis and Management of Type 2 Diabetic Kidney Disease
Simit Doshi, Allon N. Friedman
Clinical Journal of the American Society of Nephrology (2017) Vol. 12, Iss. 8, pp. 1366-1373
Open Access | Times Cited: 303
Simit Doshi, Allon N. Friedman
Clinical Journal of the American Society of Nephrology (2017) Vol. 12, Iss. 8, pp. 1366-1373
Open Access | Times Cited: 303
Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin
Ralph A. DeFronzo, Andrew Lewin, Sanjay Patel, et al.
Diabetes Care (2015) Vol. 38, Iss. 3, pp. 384-393
Open Access | Times Cited: 269
Ralph A. DeFronzo, Andrew Lewin, Sanjay Patel, et al.
Diabetes Care (2015) Vol. 38, Iss. 3, pp. 384-393
Open Access | Times Cited: 269
Diabetic nephropathy: diagnosis and treatment
Daniel Fineberg, Karin Jandeleit‐Dahm, Mark E. Cooper
Nature Reviews Endocrinology (2013) Vol. 9, Iss. 12, pp. 713-723
Closed Access | Times Cited: 264
Daniel Fineberg, Karin Jandeleit‐Dahm, Mark E. Cooper
Nature Reviews Endocrinology (2013) Vol. 9, Iss. 12, pp. 713-723
Closed Access | Times Cited: 264
Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
Ofri Mosenzon, Gil Leibowitz, Deepak L. Bhatt, et al.
Diabetes Care (2016) Vol. 40, Iss. 1, pp. 69-76
Open Access | Times Cited: 236
Ofri Mosenzon, Gil Leibowitz, Deepak L. Bhatt, et al.
Diabetes Care (2016) Vol. 40, Iss. 1, pp. 69-76
Open Access | Times Cited: 236
Diabetic nephropathy: an insight into molecular mechanisms and emerging therapies
Annabelle M. Warren, Søren Tang Knudsen, Mark E. Cooper
Expert Opinion on Therapeutic Targets (2019) Vol. 23, Iss. 7, pp. 579-591
Closed Access | Times Cited: 217
Annabelle M. Warren, Søren Tang Knudsen, Mark E. Cooper
Expert Opinion on Therapeutic Targets (2019) Vol. 23, Iss. 7, pp. 579-591
Closed Access | Times Cited: 217
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
Hiddo J.L. Heerspink, Eva Johnsson, Ingrid Gause‐Nilsson, et al.
Diabetes Obesity and Metabolism (2016) Vol. 18, Iss. 6, pp. 590-597
Open Access | Times Cited: 177
Hiddo J.L. Heerspink, Eva Johnsson, Ingrid Gause‐Nilsson, et al.
Diabetes Obesity and Metabolism (2016) Vol. 18, Iss. 6, pp. 590-597
Open Access | Times Cited: 177
Diabetic Kidney Disease: Challenges, Advances, and Opportunities
Ya Chen, Kyung Lee, Zhaohui Ni, et al.
Kidney Diseases (2020) Vol. 6, Iss. 4, pp. 215-225
Open Access | Times Cited: 141
Ya Chen, Kyung Lee, Zhaohui Ni, et al.
Kidney Diseases (2020) Vol. 6, Iss. 4, pp. 215-225
Open Access | Times Cited: 141
The gut–renal axis: do incretin-based agents confer renoprotection in diabetes?
Marcel H.A. Muskiet, Mark M. Smits, Linde M. Morsink, et al.
Nature Reviews Nephrology (2013) Vol. 10, Iss. 2, pp. 88-103
Closed Access | Times Cited: 170
Marcel H.A. Muskiet, Mark M. Smits, Linde M. Morsink, et al.
Nature Reviews Nephrology (2013) Vol. 10, Iss. 2, pp. 88-103
Closed Access | Times Cited: 170
DPP4 in Cardiometabolic Disease
Jixin Zhong, Andrei Maiseyeu, Stephen N. Davis, et al.
Circulation Research (2015) Vol. 116, Iss. 8, pp. 1491-1504
Open Access | Times Cited: 167
Jixin Zhong, Andrei Maiseyeu, Stephen N. Davis, et al.
Circulation Research (2015) Vol. 116, Iss. 8, pp. 1491-1504
Open Access | Times Cited: 167
The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes
David Z.I. Cherney, Søren S. Lund, Bruce A. Perkins, et al.
Diabetologia (2016) Vol. 59, Iss. 9, pp. 1860-1870
Open Access | Times Cited: 167
David Z.I. Cherney, Søren S. Lund, Bruce A. Perkins, et al.
Diabetologia (2016) Vol. 59, Iss. 9, pp. 1860-1870
Open Access | Times Cited: 167
Therapeutic approaches to diabetic nephropathy—beyond the RAS
Beatriz Fernández‐Fernández, Alberto Ortíz, Carmen Gómez‐Guerrero, et al.
Nature Reviews Nephrology (2014) Vol. 10, Iss. 6, pp. 325-346
Closed Access | Times Cited: 165
Beatriz Fernández‐Fernández, Alberto Ortíz, Carmen Gómez‐Guerrero, et al.
Nature Reviews Nephrology (2014) Vol. 10, Iss. 6, pp. 325-346
Closed Access | Times Cited: 165
Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS
Jan H. Cornel, George L. Bakris, Susanna R. Stevens, et al.
Diabetes Care (2016) Vol. 39, Iss. 12, pp. 2304-2310
Open Access | Times Cited: 165
Jan H. Cornel, George L. Bakris, Susanna R. Stevens, et al.
Diabetes Care (2016) Vol. 39, Iss. 12, pp. 2304-2310
Open Access | Times Cited: 165
Targeting inflammation in diabetes: Newer therapeutic options
Neeraj Agrawal, S. Kant
World Journal of Diabetes (2014) Vol. 5, Iss. 5, pp. 697-697
Open Access | Times Cited: 162
Neeraj Agrawal, S. Kant
World Journal of Diabetes (2014) Vol. 5, Iss. 5, pp. 697-697
Open Access | Times Cited: 162
The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
Angelo Avogaro, Gian Paolo Fadini
Diabetes Care (2014) Vol. 37, Iss. 10, pp. 2884-2894
Open Access | Times Cited: 149
Angelo Avogaro, Gian Paolo Fadini
Diabetes Care (2014) Vol. 37, Iss. 10, pp. 2884-2894
Open Access | Times Cited: 149
Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities
Giovanni Musso, Maurizio Cassader, S. Cohney, et al.
Diabetes Care (2016) Vol. 39, Iss. 10, pp. 1830-1845
Open Access | Times Cited: 146
Giovanni Musso, Maurizio Cassader, S. Cohney, et al.
Diabetes Care (2016) Vol. 39, Iss. 10, pp. 1830-1845
Open Access | Times Cited: 146
Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA ‐T2D trial
Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic, et al.
Diabetes Obesity and Metabolism (2017) Vol. 19, Iss. 11, pp. 1610-1619
Open Access | Times Cited: 132
Per‐Henrik Groop, Mark E. Cooper, Vlado Perkovic, et al.
Diabetes Obesity and Metabolism (2017) Vol. 19, Iss. 11, pp. 1610-1619
Open Access | Times Cited: 132
Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets
Jonatan Barrera‐Chimal, Frédéric Jaisser
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. S1, pp. 16-31
Open Access | Times Cited: 131
Jonatan Barrera‐Chimal, Frédéric Jaisser
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. S1, pp. 16-31
Open Access | Times Cited: 131
The potential for renoprotection with incretin-based drugs
Tetsuhiro Tanaka, Yoshiki Higashijima, Takehiko Wada, et al.
Kidney International (2014) Vol. 86, Iss. 4, pp. 701-711
Open Access | Times Cited: 119
Tetsuhiro Tanaka, Yoshiki Higashijima, Takehiko Wada, et al.
Kidney International (2014) Vol. 86, Iss. 4, pp. 701-711
Open Access | Times Cited: 119
Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
Vlado Perkovic, Rajiv Agarwal, Paola Fioretto, et al.
Kidney International (2016) Vol. 90, Iss. 6, pp. 1175-1183
Open Access | Times Cited: 119
Vlado Perkovic, Rajiv Agarwal, Paola Fioretto, et al.
Kidney International (2016) Vol. 90, Iss. 6, pp. 1175-1183
Open Access | Times Cited: 119
